Windtree Therapeutics (NasdaqCM:WINT) has announced that an abstract discussing the positive results of SEISMiC, its Phase 2b study of istaroximine in cardiogenic shock, was presented by Dr. Matteo Pagnesi, a cardiologist at Spedali Civili di Brescia, Italy, during the 2025 Technology and Heart Failure Therapeutics (THT) conference in Boston.
Istaroximine is a first-in-class investigational dual mechanism therapy designed to improve both systolic and diastolic cardiac function.
“We continue to see interest in istaroxime from cardiologists around the world in treating cardiogenic shock,” said Dr. Steve Simonson, CMO and SVP of Windtree.
“Windtree has prioritized cardiogenic shock as an initial indication target because of the unique profile of istaroxime effects and the positive Phase 2 studies in early cardiogenic shock. There is substantial unmet need for this patient population as currently available drugs can have unwanted side effects and poor outcomes. We are encouraged by the profile of istaroxime and look forward to progressing istaroxime toward Phase 3 in cardiogenic shock,” he added.
